rilonacept 160 mg + Placebo + rilonacept 160 mg
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Familial Cold Autoinflammatory Syndrome (FCAS)
Conditions
Familial Cold Autoinflammatory Syndrome (FCAS), Familial Cold Urticaria, Muckle-Wells Syndrome (MWS), Genetic Diseases, Inborn
Trial Timeline
Dec 1, 2005 → Aug 1, 2008
NCT ID
NCT00288704About rilonacept 160 mg + Placebo + rilonacept 160 mg
rilonacept 160 mg + Placebo + rilonacept 160 mg is a phase 3 stage product being developed by Regeneron Pharmaceuticals for Familial Cold Autoinflammatory Syndrome (FCAS). The current trial status is completed. This product is registered under clinical trial identifier NCT00288704. Target conditions include Familial Cold Autoinflammatory Syndrome (FCAS), Familial Cold Urticaria, Muckle-Wells Syndrome (MWS).
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00288704 | Phase 3 | Completed |
Competing Products
20 competing products in Familial Cold Autoinflammatory Syndrome (FCAS)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Bromocriptine Mesilate + Placebos | Towa Pharmaceutical | Phase 1/2 | 40 |
| SHR-1209 | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| SHR-1209 ;placebo + SHR-1209 ;placebo + SHR-1209 ;placebo | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Rosuvastatin 20mg + Placebo | AstraZeneca | Phase 3 | 77 |
| rosuvastatin calcium + rosuvastatin calcium + rosuvastatin calcium | AstraZeneca | Phase 3 | 77 |
| Rosuvastatin + Placebo | AstraZeneca | Phase 3 | 77 |
| Rosuvastatin 20mg | AstraZeneca | Phase 3 | 77 |
| AZD0780 + Placebo | AstraZeneca | Phase 3 | 77 |
| Anacetrapib + Placebo for anacetrapib | Merck | Phase 3 | 77 |
| Statins and Ezetimibe | Merck | Pre-clinical | 23 |
| Comparator: niacin (+) laropiprant (MK0524A) + Comparator: placebo | Merck | Phase 3 | 77 |
| MK-0524A + MK-0524A | Merck | Phase 1 | 33 |
| Enlicitide Decanoate + Placebo | Merck | Phase 2/3 | 65 |
| Inclisiran + Placebo | Novartis | Phase 3 | 77 |
| DFV890 | Novartis | Phase 2 | 52 |
| Canakinumab | Novartis | Phase 2 | 52 |
| Inclisiran Sodium for injection + Placebo + Placebos | Novartis | Phase 3 | 77 |
| LCQ908 + Placebo | Novartis | Phase 3 | 77 |
| Inclisiran | Novartis | Phase 3 | 77 |
| Inclisiran + Placebo | Novartis | Phase 3 | 77 |